Jan A. Burger, MD, PhD

home / authors / jan-a-burger-md-phd

Articles

Jan A. Burger, MD, PhD, on Long-Term Outcomes with Ibrutinib in High-Risk Patients with CLL/SLL

December 7th 2020

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.

Jan A. Burger, MD, PhD, on CLL Research Coming Out of ASH

Jan A. Burger, MD, PhD

December 6th 2020

The leukemia expert discussed exciting research being presented at this year’s ASH Annual Meeting.

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Published: August 9th 2024 | Updated: August 14th 2024

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

Published: June 2nd 2024 | Updated: June 3rd 2024

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

Published: November 7th 2024 | Updated: November 21st 2024

Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient

Published: November 7th 2024 | Updated: November 21st 2024

Treatment Considerations for Disease Progression

Published: November 7th 2024 | Updated: November 21st 2024

Treatment Paradigm for Metastatic Pancreatic Cancer

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777